Lisata Therapeutics, Inc.

Targeted Therapies Delivered

[Lisata Therapeutics, Inc. @lisata_tx]

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

Press release: https://t.co/d0AatvldOx

[Proactive @proactive_x]

$LSTA Lisata Therapeutics to be acquired by Kuva Labs in $4-per-share cash deal https://t.co/gK7DJDZubk @lisata_tx $8NE #LSTA #8NE

[Lisata Therapeutics, Inc. @lisata_tx]

Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

Read full press release: https://t.co/6Q1GeDvckT

[Lisata Therapeutics, Inc. @lisata_tx]

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more: https://t.co/owsdVjeRWd

#LisataTherapeutics

[Lisata Therapeutics, Inc. @lisata_tx]

Join us today for our 3Q 2025 Financial Results Conference Call at 4:30pm ET. To join, please refer to the dial-in info below:

Participant Toll-Free dial: [phone]
Participant Toll/Int'l dial: [phone]
Conference ID: 6375221

Webcast: https://t.co/ntTiWh0lEG

[Lisata Therapeutics, Inc. @lisata_tx]

Lisata Therapeutics is proud to announce we have been named ‘Overall BioPharma Solution of the Year’ in the 5th Annual BioTech Breakthrough Awards program conducted by @TopTechAwards.

Read more: https://t.co/2aG4Tkqe7G

#BioTechBreakthrough #BioPharma #LisataTherapeutics

[Lisata Therapeutics, Inc. @lisata_tx]

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent. Read press release: https://t.co/IbEpQ1A7aV

#LisataTherapeutics $LSTA

[Lisata Therapeutics, Inc. @lisata_tx]

On November 6, we will announce our Q3 2025 Financial Results after the close of trading and will host a conference call at 4:30 p.m. ET.
To participate on the call:
Participant Toll-Free dial: [phone]
Participant Toll/Int'l dial: [phone]
Conference ID: 6375221

[Lisata Therapeutics, Inc. @lisata_tx]

#ICYMI: Preliminary CENDIFOX data was presented at @AACR last month, showing certepetide + FOLFIRINOX was safe & feasible in pancreatic cancer patients with encouraging efficacy signals.

Read more: https://t.co/tuxY11vJCt

#LisataTherapeutics

[Lisata Therapeutics, Inc. @lisata_tx]

Our CENDIFOX data featured in @CancerNetwork, highlighting encouraging preliminary results with certepetide + FOLFIRINOX in pancreatic cancer patients.

Read the coverage: https://t.co/PkNCOHlIxs

#LisataTherapeutics #PancreaticCancer

[Lisata Therapeutics, Inc. @lisata_tx]

The CendR Platform® addresses a critical challenge: dense tumor barriers that prevent drugs from reaching cancer cells. Certepetide activates a novel uptake pathway for enhanced, selective drug delivery to solid tumors.

Learn more: https://t.co/YikbXUKimQ

#LisataTherapeutics

[Lisata Therapeutics, Inc. @lisata_tx]

Proud to announce that our CendR Platform® is a finalist for the Fierce Innovation Awards: Life Sciences Edition in the Drug Delivery Technology category. Winners announced Nov 19th.
#FierceLifeSciencesAwards #FierceInnovationAwards @LifeSciEvents

[Lisata Therapeutics, Inc. @lisata_tx]

Lisata Therapeutics to Present at LD Micro Main Event XIX

Read the press release for details: https://t.co/mtxFXkLLzS

#LisataTherapeutics

[Catalent @Catalent_]

Catalent and @lisata_tx have entered a global license agreement to develop next-gen ADCs using our SMARTag® platform and Lisata’s certepetide product candidate—advancing targeted cancer therapies.

Read the full press release: https://t.co/HTm3TkVkU3

#ADCs #SMARTag #Biologics

[Lisata Therapeutics, Inc. @lisata_tx]

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

Read the press release for details: https://t.co/oZKuJUvshY

#LisataTherapeutics

[Lisata Therapeutics, Inc. @lisata_tx]

Today we recognize #WorldCancerResearchDay and the critical role of research in improving cancer treatment. At Lisata, our CendR Platform® and certepetide aim to enhance drug delivery to solid tumors, contributing to better patient outcomes. #CancerResearch

[Lisata Therapeutics, Inc. @lisata_tx]

Today our CEO David J. Mazzo, PhD joined the FDA CEO Forums in Raleigh, calling for a public-private working group to maximize AI benefits in drug development while maintaining FDA's high safety & efficacy standards.

Collaboration drives innovation.

#FDA #AI #Innovation

[Lisata Therapeutics, Inc. @lisata_tx]

#ICYMI: Our certepetide population pharmacokinetic study was published in @ACCP1_org journal in January. The analysis provides insights to inform dose optimization in ongoing trials.

Read more: https://t.co/rw9yrS7x6q

#LisataTherapeutics

[Lisata Therapeutics, Inc. @lisata_tx]

Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Read the press release for details: https://t.co/iJvbBfUMzr

#LisataTherapeutics

[Lisata Therapeutics, Inc. @lisata_tx]

Certepetide’s unique mechanism: 1) Targets tumor-specific integrins 2) Creates CendR fragment binding to neuropilin-1 3) Activates uptake pathway 4) Enhances drug penetration in tumors while sparing healthy tissue.

Learn more: https://t.co/mspDp151A5

#CancerResearch